Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial.
From Our Partners at VerusMed
verusmed.com
Sponsored by The Doctor’s Channel
Rituximab failed to meet the primary endpoint of stemming the progression of primary-progressive multiple sclerosis (PPMS) in a Phase II/III trial.
From Our Partners at VerusMed
verusmed.com
Sponsored by The Doctor’s Channel